MedWatch

Danish biotech company considers global partnership

One of Denmark’s most promising biotech companies has introduced one of its great drug-hopes for the first time at the recently held J.P. Morgan conference in San Francisco.

Foto: Colourbox

The chairman of the Danish biotech company Forward Pharma has previously revealed that the company is developing a groundbreaking drug for the treatment of psoriasis.

Last week at the J.P. Morgan conference Forward Pharma shed even more light on the future for its promising candidate drug and presented the companyto the major players of the pharmaceutical industry. The purpose was to assess the opportunity for a global partnership as an alternative to commercializing the company on its own, says COO Peder Andersen in an interview with the journal BioCentury.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

KU søger chef til nyt life science-program

Københavns Universitet har indledt jagten på den programdirektør, der skal stå i spidsen for innovationsprogrammet Spark Denmark, som Novo Nordisk Fonden forleden kastede 44 mio. kr. efter for at bringe flere akademiske projekter indenfor farma, medico, sundhedsteknologi og industriel biotek til markedet.

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier